Medullary thyroid cancer prevention

Medullary thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Medullary thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Medullary thyroid cancer prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Medullary thyroid cancer prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Medullary thyroid cancer prevention
CDC on Medullary thyroid cancer prevention
Medullary thyroid cancer prevention in the news
Blogs on Medullary thyroid cancer prevention
Directions to Hospitals Treating Medullary thyroid cancer
Risk calculators and risk factors for Medullary thyroid cancer prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.

Prevention

• According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.

Surveillance of medullary thyroid cancer
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/